Search company, investor...
Singular Genomics company logo

Singular Genomics

singulargenomics.com

Founded Year

2016

Stage

IPO | IPO

Date of IPO

5/27/2021

Market Cap

0.13B

Stock Price

1.92

About Singular Genomics

Singular Genomics (NASDAQ: OMIC) develops a third-gen DNA sequencing system. The sequencing by synthesis system is based on technology licensed out of Jingyue Ju's lab at Columbia.

Headquarters Location

10931 N. Torrey Pines Road #100

La Jolla, California, 92037,

United States

Compete with Singular Genomics?

Ensure that your company and products are accurately represented on our platform.

Singular Genomics's Products & Differentiators

    G4 Integrated Solution

    The G4 Instrument is a benchtop next-generation sequencer designed to produce fast and accurate genetic sequencing results for specific targeted applications, including rare variant detection with high definition and synthetic long read (SLR) sequencing, which can be applied in rapidly growing markets such as oncology, including liquid biopsy detection of cell-free DNA, and immune response profiling to help researchers better harness the immune system in fighting infectious diseases, autoimmune disorders and immunotherapies for cancer.

Expert Collections containing Singular Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Singular Genomics is included in 1 Expert Collection, including Omics.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Singular Genomics Patents

Singular Genomics has filed 1 patent.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/29/2022

12/6/2022

DNA sequencing, Molecular biology, Genomics, Biotechnology, Genetics

Grant

Application Date

5/29/2022

Grant Date

12/6/2022

Title

Related Topics

DNA sequencing, Molecular biology, Genomics, Biotechnology, Genetics

Status

Grant

Latest Singular Genomics News

Singular Genomics Inks Sample Prep Partnerships With Paragon Genomics, Claret Bioscience, Reports Q3

Nov 8, 2022

Save for later NEW YORK – Singular Genomics Systems said on Monday that it has signed partnerships with Paragon Genomics and Claret Bioscience to validate its library preparation assays for use with the firm's G4 sequencer. The announcement came as the firm reported its third quarter operating results. The San Diego-based sequencing technology firm continued to report no revenues but said it will ship its first G4 sequencers in Q4. On average, Wall Street analysts had expected revenues of $70,000, though in August the firm reported that supply chain issues would impair its ability to scale up manufacturing of its sequencer. Singular's net loss for the quarter totaled $23.8 million, or $.33 per share, compared to a loss of $17.6 million, or $.25 per share, in Q3 2021, beating the consensus Wall Street estimate of a $.41 loss per share. The firm reported $12.7 million in R&D expenses, up 43 percent year over year from $8.9 million. SG&A expenses were $12.0 million, up 40 percent from $8.6 million a year ago. As of Sept. 30, Singular had $93.3 million in cash and cash equivalents and $170.6 million in short-term investments. In Tuesday morning trading on the Nasdaq, shares of Singular were up 5 percent at $2.35. Singular now has partnerships with more than half a dozen other companies on sequencing sample preparation.

Singular Genomics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Singular Genomics Rank

Singular Genomics Frequently Asked Questions (FAQ)

  • When was Singular Genomics founded?

    Singular Genomics was founded in 2016.

  • Where is Singular Genomics's headquarters?

    Singular Genomics's headquarters is located at 10931 N. Torrey Pines Road, La Jolla.

  • What is Singular Genomics's latest funding round?

    Singular Genomics's latest funding round is IPO.

  • Who are the investors of Singular Genomics?

    Investors of Singular Genomics include ARCH Venture Partners.

  • Who are Singular Genomics's competitors?

    Competitors of Singular Genomics include Pacific Biosciences and 2 more.

  • What products does Singular Genomics offer?

    Singular Genomics's products include G4 Integrated Solution and 1 more.

  • Who are Singular Genomics's customers?

    Customers of Singular Genomics include Sanford Burnham and Fate Therapeutics.

Compare Singular Genomics to Competitors

A
Algorithmic Biologics

Algorithmic Biologic's vision is to create a bountiful world by bringing intelligence to molecules. Its transdisciplinary team has a modeling-based understanding of the chemistry and mechanics of molecular technologies. The company's first product, Tapestry, is a regulatory-approved, algorithmic solution to provide affordable, large-scale COVID-19 testing.

S
Sequentify

Sequentify provides a technology that is based on tools from the synthetic biology and AI software worlds for targeted DNA sequencing applications, such as cancer diagnostics, carrier screening, COVID-19 surveillance, and other applications. It was founded in 2021 and is based in Rehovot, Israel.

E
EcoAlert

Plymouth Marine Laboratory (PML) has been conducting research into marine organisms for more than 20 years funded by NERC. EcoAlert Ltd has been formed by PML's wholly owned technology transfer company, Plymouth Marine Applications Ltd (PMA), to commercialise a bioassay technique arising from this work. The Company has exclusive rights to ECOBOX, a portable bioassay kits for in-situ analysis of marine, estuarine and freshwater aquatic environments.

Panakeia Logo
Panakeia

Panakeia makes cancer diagnosis simpler, faster and cheaper by eliminating the need for multiple tests.

Everist Health Logo
Everist Health

Everist Health (formerly Everist Genomics and Genetics Squared) is a personalized medicine company which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies. Through their tools, the company seeks to help physicians improve medical outcomes and reduce the total cost of care. EGI's products integrate with mobile digital services, smartphones, and tablet computers resulting in advanced medical technology.

Z
Zyomyx

Zyomyx a privately held diagnostics company based in Fremont, California, is an innovator in the development and commercialization of diagnostic platforms. The Zyomyx product development infrastructure and suite of proprietary assay and surface technologies are ideally suited for the development of affordable, disposable point-of-care diagnostic products, designed to increase access to testing. Zyomyx's first product is an advanced but simple and inexpensive CD4 T-cell point-of-care test that will be launched globally and is configured to meet the needs of developing countries.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.